MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

CareDx Inc

Fechado

SetorSaúde

17.3 -5.93

Visão Geral

Variação de preço das ações

24h

Atual

Mín

16.66

Máximo

18.3

Indicadores-chave

By Trading Economics

Rendimento

85M

78M

Vendas

3.7M

87M

P/E

Médio do Setor

19.086

63.778

EPS

0.18

Margem de lucro

90.103

Funcionários

644

EBITDA

-1.6M

-7.2M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+51.33% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-151M

995M

Abertura anterior

23.23

Fecho anterior

17.3

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

CareDx Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2025, 23:04 UTC

Principais Notícias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 de abr. de 2025, 22:40 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 de abr. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 de abr. de 2025, 18:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 de abr. de 2025, 23:43 UTC

Conversa de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 de abr. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 de abr. de 2025, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 21:43 UTC

Principais Notícias
Ganhos

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de abr. de 2025, 20:43 UTC

Conversa de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 de abr. de 2025, 20:34 UTC

Principais Notícias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 de abr. de 2025, 20:23 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 de abr. de 2025, 19:21 UTC

Conversa de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 de abr. de 2025, 19:15 UTC

Conversa de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 de abr. de 2025, 18:39 UTC

Conversa de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 de abr. de 2025, 18:38 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 18:30 UTC

Principais Notícias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 de abr. de 2025, 18:20 UTC

Conversa de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 de abr. de 2025, 18:18 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:17 UTC

Conversa de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 de abr. de 2025, 18:04 UTC

Conversa de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 de abr. de 2025, 17:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

CareDx Inc Previsão

Preço-alvo

By TipRanks

51.33% parte superior

Previsão para 12 meses

Média 27.83 USD  51.33%

Máximo 35 USD

Mínimo 23.5 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para CareDx Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

17.87 / 19.61Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.